Drug intelligence / Profile preview

S-PCT3010

Development stage: Preclinical
Lead developer: PolyCore Therapeutics
Modality: Small Molecules

Overview

**S-PCT3010** is a small molecule drug developed by Polycore Therapeutics for Parkinson's disease. It acts as a dual modulator, selectively activating dopamine D3 receptors without causing desensitization while inhibiting norepinephrine transporters in the brain. This novel mechanism reduces motor symptoms and improves mild cognitive impairment in preclinical rodent models, addressing gaps in current therapies like L-DOPA that can worsen cognition.

Targets

DRD3 (Dopamine receptor D3)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on S-PCT3010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-PCT3010.

Explore the full profile